254 Results
Humana, Medical Mutual of Ohio and Preferred One independently determined and published a policy stating that VeriStrat can be considered medically necessary for patients with (NSCLC)
Results from an exploratory analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.
Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)
Biodesix, in partnership with BioRad and Qiagen, presents data from new studies at AMP.
Blood-based diagnostic approach to PD-L1 testing that shows concordance with immunohistochemistry; new data presented at EORTC
CE Mark clears Biodesix to make VeriStrat results available to physicians in the European Union and other countries recognizing the CE Mark.
Biodesix and Progenetics have entered into an international agreement; Biodesix tests will be available in Israel for the first time.
Biodesix announced today that the company closed an $8.3 million Series E preferred equity financing. Existing shareholders provided all of the capital.
Biodesix has closed a structured debt financing with Capital Royalty Partners L.P. The transaction provides Biodesix®with up to $20 million of capital.
Biodesix increases the size of its recent offering of series E preferred shares in a follow-on sale; Total series E preferred shares of $14.4 million.